Summary
Researchers from the National University of Singapore and the Chinese Academy of Sciences have developed a new type of nanovaccine called NICER. This vaccine targets cancer cells and cancer stem cells to prevent tumor growth and reduce the risk of cancer returning after surgery. In early lab tests, it showed promise for treating several kinds of cancer, including breast cancer and melanoma.
Key Facts
- NICER is a nanovaccine, which means it uses tiny particles to deliver treatment directly to the immune system.
- The vaccine targets both regular cancer cells and cancer stem cells, which are often resistant to treatment.
- Initial lab models showed the vaccine might help stop cancer from growing and reduce the chance of it coming back.
- NICER showed potential particularly in cases of breast cancer, melanoma, and others with aggressive tumor growth.
- Researchers noted it worked well when combined with immune checkpoint inhibitors, a type of cancer treatment that helps the immune system fight cancer.
- Further studies are needed to understand the long-term safety of the vaccine.
- This development could lead to more personalized cancer vaccines in the future.
